49 related articles for article (PubMed ID: 22419705)
1. Thyrotropin receptor autoantibody (TRAb) enhance the expression of thyrotropin receptor on mouse brain vascular endothelial cells: in vivo and in vitro.
Liang C; Yang H; Huang X; Kuang Y; Deng X; Liu Y; Luo Z
Cell Mol Biol (Noisy-le-grand); 2023 Sep; 69(9):67-74. PubMed ID: 37807332
[TBL] [Abstract][Full Text] [Related]
2. Identification of key amino acid residues in a thyrotropin receptor monoclonal antibody epitope provides insight into its inverse agonist and antagonist properties.
Chen CR; McLachlan SM; Rapoport B
Endocrinology; 2008 Jul; 149(7):3427-34. PubMed ID: 18388191
[TBL] [Abstract][Full Text] [Related]
3. Arrestin-β-1 Physically Scaffolds TSH and IGF1 Receptors to Enable Crosstalk.
Krieger CC; Boutin A; Jang D; Morgan SJ; Banga JP; Kahaly GJ; Klubo-Gwiezdzinska J; Neumann S; Gershengorn MC
Endocrinology; 2019 Jun; 160(6):1468-1479. PubMed ID: 31127272
[TBL] [Abstract][Full Text] [Related]
4. A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves' orbitopathy.
Cui X; Wang F; Liu C
Front Immunol; 2023; 14():1062045. PubMed ID: 36742308
[TBL] [Abstract][Full Text] [Related]
5. Targeting TSH and IGF-1 Receptors to Treat Thyroid Eye Disease.
Neumann S; Krieger CC; Gershengorn MC
Eur Thyroid J; 2020 Dec; 9(Suppl 1):59-65. PubMed ID: 33511086
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of Autoantibody-Induced Pathology.
Ludwig RJ; Vanhoorelbeke K; Leypoldt F; Kaya Z; Bieber K; McLachlan SM; Komorowski L; Luo J; Cabral-Marques O; Hammers CM; Lindstrom JM; Lamprecht P; Fischer A; Riemekasten G; Tersteeg C; Sondermann P; Rapoport B; Wandinger KP; Probst C; El Beidaq A; Schmidt E; Verkman A; Manz RA; Nimmerjahn F
Front Immunol; 2017; 8():603. PubMed ID: 28620373
[TBL] [Abstract][Full Text] [Related]
7. Review of Mouse Models of Graves' Disease and Orbitopathy-Novel Treatment by Induction of Tolerance.
Ungerer M; Faßbender J; Li Z; Münch G; Holthoff HP
Clin Rev Allergy Immunol; 2017 Apr; 52(2):182-193. PubMed ID: 27368808
[TBL] [Abstract][Full Text] [Related]
8. Discovery and Development of Small Molecule Allosteric Modulators of Glycoprotein Hormone Receptors.
Nataraja SG; Yu HN; Palmer SS
Front Endocrinol (Lausanne); 2015; 6():142. PubMed ID: 26441832
[TBL] [Abstract][Full Text] [Related]
9. Graves' orbitopathy: imperfect treatments for a rare disease.
Bartalena L
Eur Thyroid J; 2013 Dec; 2(4):259-69. PubMed ID: 24783057
[TBL] [Abstract][Full Text] [Related]
10. A selective TSH receptor antagonist inhibits stimulation of thyroid function in female mice.
Neumann S; Nir EA; Eliseeva E; Huang W; Marugan J; Xiao J; Dulcey AE; Gershengorn MC
Endocrinology; 2014 Jan; 155(1):310-4. PubMed ID: 24169564
[TBL] [Abstract][Full Text] [Related]
11. Novel insights on thyroid-stimulating hormone receptor signal transduction.
Kleinau G; Neumann S; Grüters A; Krude H; Biebermann H
Endocr Rev; 2013 Oct; 34(5):691-724. PubMed ID: 23645907
[TBL] [Abstract][Full Text] [Related]
12. A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy.
Turcu AF; Kumar S; Neumann S; Coenen M; Iyer S; Chiriboga P; Gershengorn MC; Bahn RS
J Clin Endocrinol Metab; 2013 May; 98(5):2153-9. PubMed ID: 23482611
[TBL] [Abstract][Full Text] [Related]
13. Emerging pharmacotherapy for treatment of Graves' disease.
Bahn RS
Expert Rev Clin Pharmacol; 2012 Nov; 5(6):605-7. PubMed ID: 23234319
[No Abstract] [Full Text] [Related]
14. Update in TSH receptor agonists and antagonists.
Gershengorn MC; Neumann S
J Clin Endocrinol Metab; 2012 Dec; 97(12):4287-92. PubMed ID: 23019348
[TBL] [Abstract][Full Text] [Related]
15. A drug-like antagonist inhibits thyrotropin receptor-mediated stimulation of cAMP production in Graves' orbital fibroblasts.
Neumann S; Pope A; Geras-Raaka E; Raaka BM; Bahn RS; Gershengorn MC
Thyroid; 2012 Aug; 22(8):839-43. PubMed ID: 22784331
[TBL] [Abstract][Full Text] [Related]
16. Complete inhibition of rhTSH-, Graves' disease IgG-, and M22-induced cAMP production in differentiated orbital fibroblasts by a low-molecular-weight TSHR antagonist.
van Zeijl CJ; van Koppen CJ; Surovtseva OV; de Gooyer ME; Plate R; Conti P; Karstens WJ; Timmers M; Saeed P; Wiersinga WM; Miltenburg AM; Fliers E; Boelen A
J Clin Endocrinol Metab; 2012 May; 97(5):E781-5. PubMed ID: 22419705
[TBL] [Abstract][Full Text] [Related]
17. Effects of thyrotropin and thyrotropin-receptor-stimulating Graves' disease immunoglobulin G on cyclic adenosine monophosphate and hyaluronan production in nondifferentiated orbital fibroblasts of Graves' ophthalmopathy patients.
van Zeijl CJ; Fliers E; van Koppen CJ; Surovtseva OV; de Gooyer ME; Mourits MP; Wiersinga WM; Miltenburg AM; Boelen A
Thyroid; 2010 May; 20(5):535-44. PubMed ID: 20384487
[TBL] [Abstract][Full Text] [Related]
18. Thyrotropin receptor-stimulating Graves' disease immunoglobulins induce hyaluronan synthesis by differentiated orbital fibroblasts from patients with Graves' ophthalmopathy not only via cyclic adenosine monophosphate signaling pathways.
van Zeijl CJ; Fliers E; van Koppen CJ; Surovtseva OV; de Gooyer ME; Mourits MP; Wiersinga WM; Miltenburg AM; Boelen A
Thyroid; 2011 Feb; 21(2):169-76. PubMed ID: 20954819
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
